Reduce Dr Reddys; target of Rs 1300: Emkay Global Financial
Emkay Global Financial' research report on Dr ReddysDr Reddy’s’ Form 20-F disclosures indicate that gRevlimid sales in FY26 were closer to our base-case estimate (~$300mn). However, assuming muted growth in the company’s base oncology portfolio since FY22, gRevlimid contribution would have been hig…